Advanced search
Publication Cover
OncoImmunology Volume 5, 2016 - Issue 4
Submit an article Journal homepage
2,220
Views
33
CrossRef citations to date
0
Altmetric
Original Research

Trastuzumab upregulates expression of HLA-ABC and T cell costimulatory molecules through engagement of natural killer cells and stimulation of IFNγ secretion

Bharat K. R. ChagantyDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;Graduate School of Biomedical Sciences, The University of Texas Health Sciences Center at Houston, Houston, TX, USA
,
Yang LuDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Songbo QiuDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Srinivas S. SomanchiDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Dean A. LeeDepartment of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;Graduate School of Biomedical Sciences, The University of Texas Health Sciences Center at Houston, Houston, TX, USA
&
Zhen FanDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;Graduate School of Biomedical Sciences, The University of Texas Health Sciences Center at Houston, Houston, TX, USACorrespondence[email protected]
Article: e1100790 | Received 02 Jul 2015, Accepted 22 Sep 2015, Published online: 08 Apr 2016

Citations (33)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Jonathan G. Pol, Sarah Lévesque, Samuel T. Workenhe, Shashi Gujar, Fabrice Le Boeuf, Derek R. Clements, Jean-Eudes Fahrner, Laetitia Fend, John C. Bell, Karen L. Mossman, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. OncoImmunology 7:12.
Read now
Stefano Pierini, Renzo Perales-Linares, Mireia Uribe-Herranz, Jonathan G. Pol, Laurence Zitvogel, Guido Kroemer, Andrea Facciabene & Lorenzo Galluzzi. (2017) Trial watch: DNA-based vaccines for oncological indications. OncoImmunology 6:12.
Read now
Carole Fournier, François Martin, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Lionel Apetoh. (2017) Trial Watch: Adoptively transferred cells for anticancer immunotherapy. OncoImmunology 6:11.
Read now

Articles from other publishers (30)

Sofia Batalha, Catarina Monteiro Gomes & Catarina Brito. (2023) Immune microenvironment dynamics of HER2 overexpressing breast cancer under dual anti-HER2 blockade. Frontiers in Immunology 14.
Crossref
Mona M. Elanany, Dina Mostafa & Nadia M. Hamdy. (2023) Remodeled tumor immune microenvironment (TIME) parade via natural killer cells reprogramming in breast cancer. Life Sciences 330, pages 121997.
Crossref
Xiaoxue Wu, Shuting Huang, Weiling He & Mei Song. (2023) Emerging insights into mechanisms of trastuzumab resistance in HER2-positive cancers. International Immunopharmacology 122, pages 110602.
Crossref
Anna Pous, Lucía Notario, Cinta Hierro, Laura Layos & Cristina Bugés. (2023) HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies. International Journal of Molecular Sciences 24:14, pages 11403.
Crossref
Fatemeh Zahedipour, Muhammed Majeed, Prashant Kesharwani & Amirhossein Sahebkar. 2023. Aptamers Engineered Nanocarriers for Cancer Therapy. Aptamers Engineered Nanocarriers for Cancer Therapy 317 346 .
Chuan Liu, Guangwei Zhang, Kanghui Xiang, Yohan Kim, Roxane R. Lavoie, Fabrice Lucien & Ti Wen. (2021) Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy. Cancer Immunology, Immunotherapy 71:7, pages 1549-1567.
Crossref
G. Roviello, M. Catalano, L. F. Iannone, L. Marano, M. Brugia, G. Rossi, G. Aprile & L. Antonuzzo. (2022) Current status and future perspectives in HER2 positive advanced gastric cancer. Clinical and Translational Oncology 24:6, pages 981-996.
Crossref
Ashley E. Russell, Zhaohao Liao, Mercedes Tkach, Patrick M. Tarwater, Matias Ostrowski, Clotilde Théry & Kenneth W. Witwer. (2022) Cigarette smoke-induced extracellular vesicles from dendritic cells alter T-cell activation and HIV replication. Toxicology Letters 360, pages 33-43.
Crossref
Yunbi Ni, Julia Y Tsang, Yan Shao, Ivan K Poon, Fiona Tam, Ka-Ho Shea & Gary M Tse. (2022) Combining Analysis of Tumor-infiltrating Lymphocytes (TIL) and PD-L1 Refined the Prognostication of Breast Cancer Subtypes. The Oncologist 27:4, pages e313-e327.
Crossref
Xiao-Na Xiang, Si-Yi Zhu, Hong-Chen He, Xi Yu, Yang Xu & Cheng-Qi He. (2022) Mesenchymal stromal cell-based therapy for cartilage regeneration in knee osteoarthritis. Stem Cell Research & Therapy 13:1.
Crossref
Giandomenico Roviello, Giuseppe Aprile, Alberto D’Angelo, Luigi Francesco Iannone, Franco Roviello, Karol Polom, Enrico Mini & Martina Catalano. (2021) Human epidermal growth factor receptor 2 (HER2) in advanced gastric cancer: where do we stand?. Gastric Cancer 24:4, pages 765-779.
Crossref
Cinzia Vetrei, Margherita Passariello, Guendalina Froechlich, Rosa Rapuano Lembo, Nicola Zambrano & Claudia De Lorenzo. (2021) Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments. Cancers 13:12, pages 2858.
Crossref
Miganoosh Simonian, Mozhan Haji Ghaffari & Babak Negahdari. (2021) Immunotherapy for Breast Cancer Treatment. Iranian Biomedical Journal 25:3, pages 140-156.
Crossref
Kohei Yamashita, Masaaki Iwatsuki, Noriko Yasuda-Yoshihara, Takeshi Morinaga, Yosuke Nakao, Kazuto Harada, Kojiro Eto, Junji Kurashige, Yukiharu Hiyoshi, Takatsugu Ishimoto, Yohei Nagai, Shiro Iwagami, Yoshifumi Baba, Yuji Miyamoto, Naoya Yoshida, Jaffer A. Ajani & Hideo Baba. (2020) Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer. British Journal of Cancer 124:3, pages 595-603.
Crossref
Caroline Lum & Sophia Frentzas. 2021. Research and Clinical Applications of Targeting Gastric Neoplasms. Research and Clinical Applications of Targeting Gastric Neoplasms 317 342 .
Yuqing Cao, Xiaoyu Wang, Tianqiang Jin, Yu Tian, Chaoliu Dai, Crystal Widarma, Rui Song & Feng Xu. (2020) Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduction and Targeted Therapy 5:1.
Crossref
Alessandra Jordano Conforte, Leon Alves, Flávio Codeço Coelho, Nicolas Carels & Fabrício Alves Barbosa da Silva. (2020) Modeling Basins of Attraction for Breast Cancer Using Hopfield Networks. Frontiers in Genetics 11.
Crossref
Seiichiro Mitani & Hisato Kawakami. (2020) Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance. Cancers 12:2, pages 400.
Crossref
Margherita Passariello, Simona Camorani, Cinzia Vetrei, Stefania Ricci, Laura Cerchia & Claudia De Lorenzo. (2020) Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells. Cancers 12:2, pages 331.
Crossref
Ming-Zhen Zhao, Yu Sun, Xiao-Feng Jiang, Li Liu, Li Liu & Li-Xin Sun. (2020) Promotion on NLRC5 upregulating MHC-I expression by IFN-γ in MHC-I–deficient breast cancer cells. Immunologic Research 67:6, pages 497-504.
Crossref
Marilina García-Aranda & Maximino Redondo. (2019) Immunotherapy: A Challenge of Breast Cancer Treatment. Cancers 11:12, pages 1822.
Crossref
Margaret E. Gatti-Mays, Justin M. Balko, Sofia R. Gameiro, Harry D. Bear, Sangeetha Prabhakaran, Jami Fukui, Mary L. Disis, Rita Nanda, James L. Gulley, Kevin Kalinsky, Houssein Abdul Sater, Joseph A. Sparano, David Cescon, David B. Page, Heather McArthur, Sylvia Adams & Elizabeth A. Mittendorf. (2019) If we build it they will come: targeting the immune response to breast cancer. npj Breast Cancer 5:1.
Crossref
Dean A. Lee. (2019) Cellular therapy: Adoptive immunotherapy with expanded natural killer cells. Immunological Reviews 290:1, pages 85-99.
Crossref
François Ghiringhelli. (2018) Nouvelles stratégies innovantes en immunothérapie. Bulletin du Cancer 105, pages S101-S112.
Crossref
Giuseppe Gullo, Naomi Walsh, David Fennelly, Reetesh Bose, Janice Walshe, Dimitrios Tryfonopoulos, Kate O’Mahony, Lisa Hammond, Nuno Silva, Deirdre McDonnell, Josephine Ballot, Cecily Quinn, Enda W. McDermott, Denis Evoy, Ruth Prichard, James Geraghty, John Amstrong & John Crown. (2018) Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project. British Journal of Cancer 119:3, pages 374-380.
Crossref
Bharat K.R. Chaganty, Songbo Qiu, Anneliese Gest, Yang Lu, Cristina Ivan, George A. Calin, Louis M. Weiner & Zhen Fan. (2018) Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion. Cancer Letters 430, pages 47-56.
Crossref
François Ghiringhelli. (2018) WITHDRAWN: Nouvelles stratégies innovantes en immunothérapie. Bulletin du Cancer.
Crossref
Aura Muntasell, Mariona Cabo, Sonia Servitja, Ignasi Tusquets, María Martínez-García, Ana Rovira, Federico Rojo, Joan Albanell & Miguel López-Botet. (2017) Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy. Frontiers in Immunology 8.
Crossref
Feng Xu, Alexander Sunderland, Yue Zhou, Richard D. Schulick, Barish H. Edil & Yuwen Zhu. (2017) Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions. Cancer Immunology, Immunotherapy.
Crossref
Dominic Amara, Denise M. Wolf, Laura van ’t Veer, Laura Esserman, Michael Campbell & Christina Yau. (2016) Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer. Breast Cancer Research and Treatment 161:1, pages 41-50.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.